Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shire
With
Nycomed
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed and dated informed consent prior to any study-related procedures are performed
Men and women 18 years of age or older at the time of informed consent signing
Intestinal failure resulting in Short Bowel Syndrome
At least 12 months of continuous PN dependency
12 weeks of clinical remission of Crohn's disease (CD) prior to dosing
PN required at least 3 times weekly
A stable PN volume for four weeks prior to dosing
You may not be if
History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state
Participation in clinical study within 30 days for drug or 90 days for antibody
Use of native GLP-2 or human growth hormone (HGH) within 6 months of screening
Use of iv glutamine within 30 days prior to screening
Use of teduglutide
CD patients who have been treated with biological therapy within 6 months of screening
IBD patients who require chronic systemic immunosuppressant therapy
More than 4 SBS- or PN-related hospitalizations within 12 months of screening
Unplanned hospitalization within one month of screening
Pregnant or lactating women
Body weight \> 88kg
Body mass index (BMI) \< 15 kg/m2
Severe hepatic impairment or disturbed renal function
Female subjects who are not surgically sterile or postmenopausal or who are not using medically acceptable methods of birth control during and for 30 days after the treatment period
Not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements
Any condition or circumstance that is the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with the analysis of the study results